SCHEMBL4360010

SCHEMBL4360010

O=C(NCCc1ccccc1)Nc1cccc(Cl)c1O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.64
TRPV1 Q8NER1 3/20 0.58
NPC1 O15118 3/20 0.58
RAB9A P51151 3/20 0.58
CNR1 P21554 3/20 0.58
KMT2A Q03164 4/20 0.58
MEN1 O00255 3/20 0.58
MAPT P10636 1/20 0.58
CASR P41180 1/20 0.52
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA9 Q16790 1/20 0.52
EPHX1 P07099 2/20 0.51
MAPK1 P28482 1/20 0.51
PTPN7 P35236 1/20 0.51
DUSP3 P51452 1/20 0.51
PTPN5 P54829 1/20 0.51
PTPN11 Q06124 1/20 0.51
TAAR1 Q96RJ0 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4345948 0.86 KDM4E (0.62) SMN1; SMN2TRPV1RAB9AKMT2AMEN1
SCHEMBL4345315 0.84 CNR1 (0.59) SMN1; SMN2TRPV1NPC1RAB9ACNR1
SCHEMBL4351245 0.83 TRPV1 (0.58) SMN1; SMN2TRPV1NPC1RAB9ACNR1
SCHEMBL4356054 0.83 MAPK1 (0.70) SMN1; SMN2NPC1RAB9AKMT2AMEN1
SCHEMBL19472652 0.82 SMN1; SMN2 (0.73) SMN1; SMN2TRPV1NPC1RAB9ACNR1
SCHEMBL4351106 0.79 CNR1 (0.68) SMN1; SMN2NPC1RAB9ACNR1KMT2A
SCHEMBL27782809 0.79 POLB (0.61) SMN1; SMN2KMT2AMEN1MAPTCASR
SCHEMBL4605886 0.79 CXCR2 (0.62) SMN1; SMN2TRPV1NPC1RAB9ACNR1
SCHEMBL14433772 0.78 KMT2A (0.66) SMN1; SMN2NPC1RAB9ACNR1KMT2A
SCHEMBL4341271 0.78 NPC1 (0.52) SMN1; SMN2TRPV1NPC1RAB9ACNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 SMN1; SMN2 1791/4885TRPV1 2328/4885NPC1 815/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 SMN1; SMN2 3250/4885TRPV1 2320/4885NPC1 1189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.